Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer

June 22, 2026 updated by: University of California, Davis

EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at tumor tissue samples and blood samples to learn more about DNA changes in patients with lung cancer.

Study Overview

Status

Recruiting

Conditions

Lung Cancer

Detailed Description

OBJECTIVES:

Examine the mutational status of the EGFR pathway in tumor and blood samples from patients with lung cancer.
Correlate the EGFR pathway mutations in these samples with clinical outcomes of these patients.

OUTLINE: Archived tumor tissue and blood samples are analyzed via PCR to detect EGFR pathway mutations in DNA.

Study Type

Observational

Enrollment (Estimated)

800

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Office of Clinical Research
Phone Number: 916-382-6970
Email: OCRReferral@health.ucdavis.edu

Study Locations

United States
- California
  - Sacramento, California, United States, 95817
    - Recruiting
    - University of California Davis Cancer Center
    - Contact:
      
      Office of Clinical Research
      
      Phone Number: 916-382-6970
      
      Email: OCRReferral@health.ucdavis.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Sampling Method

Non-Probability Sample

Study Population

Patients with lung cancer

Description

DISEASE CHARACTERISTICS:

Histologically or cytologically confirmed lung cancer

PATIENT CHARACTERISTICS:

Not specified

PRIOR CONCURRENT THERAPY:

May have received prior EGFR inhibitors

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Observational Models: Cohort
Time Perspectives: Prospective

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort
Patients with lung cancer Collection of archival tumor specimen at the beginning of the study and collection of blood samples at the beginning of the study and then at regular intervals

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Mutational status of the EGFR pathway Time Frame: up to 1 year	up to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of California, Davis

Investigators

Principal Investigator: Jonathan Riess, MD, University of California, Davis

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Learn more or sign up for the study here!

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 19, 2004

Primary Completion (Estimated)

May 1, 2034

Study Completion (Estimated)

May 1, 2034

Study Registration Dates

First Submitted

May 9, 2009

First Submitted That Met QC Criteria